OXNARD, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a
leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets,
cannabinoid molecules and new chemical entities (NCEs), today announces it will be exhibiting at the 8th Global Drug
Delivery & Formulation (DDF) Summit in Berlin, Germany March 27-29, 2017.
“The DDF Summit is among the most prestigious international conferences related to drug formulation and development,” said Rob
Davidson, CEO of CURE Pharmaceutical. “We are anxious to share expertise among this elite group of investigators and manufacturers
and look forward to potential future developments emanating from this conference.”
About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive
proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art
cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven
therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary
molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient
compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more
information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About The 8th Global Drug Development & Formulation Summit
The growth of biopharma and patient compliance issues have encouraged us to adopt a drug delivery mindset from discovery right
through to production. The host of resulting challenges is being tackled by some of the greatest minds in pharma, academia and
technology. Every year we see innovation and breakthroughs at every level of drug development. The DDF Summit brings these
inspirational stories to you. Through exclusive case studies, brand new results and in depth analysis you’ll be at the very
forefront of modern pharmaceutical development.
The summit features 3 dedicated streams and 60 speakers across 3 days. You’ll find new technologies, concepts and contacts to help
you in areas such as:
- Oral delivery of biologics – bioavailability, modeling and innovative drug delivery systems
- Injectability of highly concentrated protein formulations
- Understanding and control of amorphous solid dispersions
- Nanoparticles – preparation, progress and future potential
- Challenges of pediatric drug delivery
- Microneedles and the latest transdermal delivery systems
Complementing the technical streamed sessions, you’ll also have keynotes from industry giants on the bigger picture of where the
industry is going. As well as academic and regulatory gurus guiding you through current approval process mine fields. It’s this
combination of industry and academic minds with common interests and goals that provide such a richly stimulating and exciting
environment.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements,
other than statements of fact, including those statements with respect to the Company's business development, are forward-looking
statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We
undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com
![](http://www.globenewswire.com/newsroom/ti?ndecode=MTg0IzY3MzQzNDI=)